Recordati

REC

IT0003828271

Pharmaceuticals

Real-time Borsa Italiana Other stock markets 15:03:29 13/01/2026 GMT			5-day change	1st Jan Change
48.40 ^EUR	-2.77%		+2.20%	-0.29%

01-12	Recordati Acquires 74,165 Own Ordinary Shares	AN
01-07	STRM.BIO, Inc. announced that it expects to receive funding from Recordati Industria Chimica e Farmaceutica S.p.A., Boehringer Ingelheim, Investment Arm, Delos Advisors Limited and other investors	CI

Recordati CEO Acquires 2,000 Ordinary Shares

Published on 12/08/2025 at 07:08 am GMT

Alliance News - Translated by Marketscreener - See original

Recordati

-2.77%

(Alliance News) - Recordati Spa announced on Monday that Chief Executive Officer Robert Koremans has purchased 2,000 ordinary shares of the company.

The shares were acquired at an average unit price of EUR49.2297, for a total consideration of EUR98,459.40.

By Claudia Cavaliere, Alliance News reporter

Comments and questions to redazione@alliancenews.com

Latest news about Recordati

01-12	Recordati Acquires 74,165 Own Ordinary Shares	AN
01-07	STRM.BIO, Inc. announced that it expects to receive funding from Recordati Industria Chimica e Farmaceutica S.p.A., Boehringer Ingelheim, Investment Arm, Delos Advisors Limited and other investors	CI
01-05	Recordati Buys Back 52,000 Own Shares for Over EUR2 Million	AN
12-31	US FDA declines to approve Corcept's drug for rare hormonal disorder	RE
12-23	Recordati Acquires 13,050 Own Shares for Approximately EUR570,000	AN
12-18	Mixed European Markets, Central Banks in the Spotlight	AN
12-17	Mixed European Markets Ahead of ECB Decision, Mib Turns Bullish	AN
12-17	Mixed results in Europe; Saipem leads the gains	AN
12-17	Mib opens higher; strength in banking stocks	AN
12-16	Recordati launches new buyback program of up to EUR55 million	AN
12-10	Felice La Corte buys 4,000 Recordati shares	AN
12-08	Mib down; MPS at the top of the list	AN
12-08	Recordati CEO Acquires 2,000 Ordinary Shares	AN
11-17	Futures show stability; macro data expected	AN
11-14	Mib Drops Below 44,000; Azimut Bucks the Trend	AN
11-13	Mib at 45,000 points; Buzzi and Azimut down sharply	AN
11-13	European Markets Set to Open Higher After End of U.S. Shutdown	AN
11-12	European Markets Climb, Mib Leads with Mediobanca	AN
11-12	Recordati Industria Chimica e Farmaceutica S.p.A., Nine Months 2025 Earnings Call, Nov 12, 2025
11-12	Mediobanca Leads Gains; Strong Performance for De' Longhi on the Mid-Cap	AN
11-12	European stocks rally; Fed and US optimism as markets reopen	AN
11-12	Recordati says 2025 profit to be hit by weak economy, currency impact	RE
11-12	Bullish markets; Mib starts again from 43,400	AN
11-12	Italy - Factors to watch on November 12	RE
11-11	Recordati Industria Chimica e Farmaceutica S.p.A. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI

Robert Koremans currently works at Recordati SpA, as Chief Executive Officer & Director.
Dr. Koremans also formerly worked at Teva Pharmaceutical Industries Ltd., as President & CEO-Global Specialty Medicines from 2013 to 2017, Esperite NV, as Chief Executive Officer & Director from 2007 to 2009, Nutreco NV, as Chairman-Executive Board & Chief Executive Officer from 2019 to 2021, Zentiva Group as, as Chief Executive Officer from 2009 to 2011, Cryo-Save CZ sro, as Chief Executive Officer from 2007 to 2009, Teva Pharmaceuticals Europe BV, as President & Chief Executive Officer from 2012 to 2013, Grünenthal GmbH, as Director from 2007 to 2008, Sanofi, as Senior VP-Generics, Strategy & Development from 1988 to 1991, and Serono Corp., as Vice President-Europe, Middle East & Africa.
Dr. Koremans received his doctorate degree from Erasmus University Rotterdam.

View full profile

Chart Recordati

Duration

Period

REC: Dynamic Chart

Company Profile

Recordati S.p.A. specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical and OTC products (64.4%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases, etc.; - medicines for rare diseases (35.6%). Net sales are distributed geographically as follows: Italy (14.3%), Europe (56.1%), America (20.4%), Asia and Oceania (6.7%) and Africa (2.5%).

Employees

4,539

Sector

Pharmaceuticals

Calendar

02-18 - Q4 2025 Earnings Release (Projected)

More about the company